PL2356462T3 - Kompozycje anty-CXCR1 oraz sposoby - Google Patents

Kompozycje anty-CXCR1 oraz sposoby

Info

Publication number
PL2356462T3
PL2356462T3 PL09826676T PL09826676T PL2356462T3 PL 2356462 T3 PL2356462 T3 PL 2356462T3 PL 09826676 T PL09826676 T PL 09826676T PL 09826676 T PL09826676 T PL 09826676T PL 2356462 T3 PL2356462 T3 PL 2356462T3
Authority
PL
Poland
Prior art keywords
methods
cxcr1
compositions
cxcr1 compositions
Prior art date
Application number
PL09826676T
Other languages
English (en)
Inventor
Max S. Wicha
Christophe Ginestier
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Publication of PL2356462T3 publication Critical patent/PL2356462T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
PL09826676T 2008-11-11 2009-11-11 Kompozycje anty-CXCR1 oraz sposoby PL2356462T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11345808P 2008-11-11 2008-11-11
EP09826676.0A EP2356462B1 (en) 2008-11-11 2009-11-11 Anti-cxcr1 compositions and methods

Publications (1)

Publication Number Publication Date
PL2356462T3 true PL2356462T3 (pl) 2017-07-31

Family

ID=42170302

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09826676T PL2356462T3 (pl) 2008-11-11 2009-11-11 Kompozycje anty-CXCR1 oraz sposoby

Country Status (26)

Country Link
US (3) US8940301B2 (pl)
EP (2) EP3153862A1 (pl)
JP (3) JP5716180B2 (pl)
KR (3) KR101588547B1 (pl)
CN (3) CN104623664B (pl)
AU (1) AU2009314141B2 (pl)
BR (1) BRPI0921150B1 (pl)
CA (1) CA2743305C (pl)
CY (1) CY1118933T1 (pl)
DK (1) DK2356462T3 (pl)
EA (1) EA023466B1 (pl)
ES (1) ES2623128T3 (pl)
HR (1) HRP20170463T1 (pl)
HU (1) HUE032623T2 (pl)
IL (1) IL212822A (pl)
LT (1) LT2356462T (pl)
MX (2) MX2011005007A (pl)
NZ (2) NZ625440A (pl)
PL (1) PL2356462T3 (pl)
PT (1) PT2356462T (pl)
RS (1) RS55784B1 (pl)
SG (1) SG10201701954QA (pl)
SI (1) SI2356462T1 (pl)
SM (1) SMT201700181T1 (pl)
WO (1) WO2010056753A1 (pl)
ZA (1) ZA201103416B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153862A1 (en) 2008-11-11 2017-04-12 The Regents of the University of Michigan Anti-cxcr1 compositions and methods
GB201106870D0 (en) * 2011-04-26 2011-06-01 Univ Belfast Marker
EP2773373B1 (en) * 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
EP2831112A1 (en) * 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
US10000575B2 (en) * 2013-04-29 2018-06-19 Ogd2 Pharma Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
JP6683986B2 (ja) * 2013-07-10 2020-04-22 国立大学法人 東京大学 がん幹細胞分子マーカー
JP7252125B2 (ja) 2016-10-03 2023-04-04 ザ チルドレンズ メディカル センター コーポレーション 糖尿病性腎症の予防および処置
CA3044030A1 (en) * 2016-11-17 2018-05-24 Nantbio, Inc. Validation of inferred anticancer pathways
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10100275B2 (en) * 2017-03-16 2018-10-16 King Faisal Specialist Hospital & Research Centre Method for generating human multipotent mammary stem cells from normal primary breast luminal cells
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
RU2702910C2 (ru) * 2018-12-20 2019-10-14 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ снижения количества стволовых клеток рака молочной железы
WO2020172233A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Treatment of prostate cancer by androgen ablation and il-8 blockade
RU2700695C2 (ru) * 2019-02-27 2019-09-19 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ снижения клоногенной активности стволовых клеток рака молочной железы
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
KR102558989B1 (ko) * 2020-01-10 2023-07-21 라이즈 바이오파마슈티컬즈, 인코포레이티드 (베이징) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
CN114075286A (zh) * 2020-08-21 2022-02-22 张家港博泽利斯生物技术有限公司 一种抗人cxcr1蛋白单克隆抗体的制备方法
WO2023032957A1 (ja) * 2021-08-30 2023-03-09 学校法人東京薬科大学 がんの予防および／または治療のための医薬組成物
CN116350787B (zh) * 2023-03-15 2025-04-01 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) Rbm15的抑制剂在卵巢癌紫杉醇化疗耐药中的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
CA2148252C (en) 1992-10-30 2007-06-12 Roger Brent Interaction trap system for isolating novel proteins
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6156305A (en) 1994-07-08 2000-12-05 Baxter International Inc. Implanted tumor cells for the prevention and treatment of cancer
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE19681033D2 (de) * 1995-11-16 1999-03-18 Michael W Dahm Verfahren zur Quantifizierung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
EP0874993A1 (en) 1995-12-22 1998-11-04 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
DE69718029T2 (de) 1996-10-11 2003-10-16 The Regents Of The University Of California, Oakland Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6198107B1 (en) 1997-03-07 2001-03-06 Clare Chemical Research, Inc. Fluorometric detection using visible light
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
JP2005511754A (ja) 2001-12-07 2005-04-28 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 乳癌幹細胞の予測的同定および特徴づけ
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
KR101291787B1 (ko) * 2003-05-30 2013-08-07 어젠시스 인코포레이티드 전립선 줄기 세포 항원 (ｐｓｃａ) 변이체 및 그의서브서열
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050142136A1 (en) * 2003-10-23 2005-06-30 Lary Suva Anti-interleukin 8 therapy for tumor osteolysis
CA2554779A1 (en) 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2005103711A2 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)
WO2005113534A2 (en) * 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
GB0417740D0 (en) 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070208074A1 (en) * 2006-01-24 2007-09-06 Bonni Azad M Methods and compositions for treating and preventing tumors
AU2007240365B2 (en) * 2006-04-21 2011-12-15 Glaxosmithkline Llc IL-8 receptor antagonists
WO2008036419A2 (en) * 2006-09-22 2008-03-27 The Regents Of The University Of Michigan Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker
JP5311439B2 (ja) * 2006-12-27 2013-10-09 日本メナード化粧品株式会社 皮膚の状態を評価する方法及びその用途
CN101126758A (zh) * 2007-09-06 2008-02-20 江苏省肿瘤医院 流式细胞术同步检测肿瘤中多种细胞蛋白表达的方法
US20110111434A1 (en) * 2008-07-15 2011-05-12 Huang Emina H Colon stem cells associated with colitisand colorectal cancer and methods of use
EP3153862A1 (en) 2008-11-11 2017-04-12 The Regents of the University of Michigan Anti-cxcr1 compositions and methods

Also Published As

Publication number Publication date
CN102272599B (zh) 2015-01-14
JP5716180B2 (ja) 2015-05-13
HK1206256A1 (en) 2016-01-08
HUE032623T2 (hu) 2017-10-30
SI2356462T1 (sl) 2017-05-31
SMT201700181T1 (it) 2017-05-08
EA201100779A1 (ru) 2011-12-30
JP2012508384A (ja) 2012-04-05
KR20140132412A (ko) 2014-11-17
EP3153862A1 (en) 2017-04-12
KR20110093893A (ko) 2011-08-18
US20150160227A1 (en) 2015-06-11
HK1206421A1 (en) 2016-01-08
JP2014037427A (ja) 2014-02-27
CN102272599A (zh) 2011-12-07
KR20150065930A (ko) 2015-06-15
JP5909783B2 (ja) 2016-04-27
EP2356462A1 (en) 2011-08-17
US9606124B2 (en) 2017-03-28
MX351889B (es) 2017-11-01
AU2009314141B2 (en) 2013-11-07
SG10201701954QA (en) 2017-05-30
AU2009314141A1 (en) 2010-05-20
CN104634972B (zh) 2017-06-13
US20100136031A1 (en) 2010-06-03
CA2743305C (en) 2017-04-04
US20150094362A1 (en) 2015-04-02
LT2356462T (lt) 2017-03-10
EP2356462B1 (en) 2017-01-04
RS55784B1 (sr) 2017-07-31
KR101588547B1 (ko) 2016-01-28
IL212822A (en) 2017-05-29
JP2016065082A (ja) 2016-04-28
CN104623664A (zh) 2015-05-20
ES2623128T3 (es) 2017-07-10
BRPI0921150B1 (pt) 2022-05-10
NZ602369A (en) 2015-02-27
US10557850B2 (en) 2020-02-11
IL212822A0 (en) 2011-07-31
PT2356462T (pt) 2017-04-07
DK2356462T3 (en) 2017-02-27
HRP20170463T1 (hr) 2017-05-19
MX2011005007A (es) 2011-07-28
BRPI0921150A2 (pt) 2020-11-17
CN104634972A (zh) 2015-05-20
HK1161350A1 (en) 2012-08-24
EA023466B1 (ru) 2016-06-30
US8940301B2 (en) 2015-01-27
EP2356462A4 (en) 2012-09-19
ZA201103416B (en) 2012-08-29
CA2743305A1 (en) 2010-05-20
CY1118933T1 (el) 2018-01-10
NZ625440A (en) 2016-01-29
CN104623664B (zh) 2018-08-07
WO2010056753A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
PT2356462T (pt) Composições e métodos anti-cxcr1
BRPI0920284A2 (pt) composição e método
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
DK2634231T3 (da) Sammensætninger
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
BRPI0912046A2 (pt) composições de hibridização e métodos
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI0917231A2 (pt) composição
EP3988147C0 (en) INSERT SET
BRPI0922084A2 (pt) Composições e métodos compreendendo variantes de serina protease
IT1392101B1 (it) Composizione comprendente isoflavoni
IL210153A0 (en) Nutrigenomics methods and compositions
EP2381760A4 (en) CORN PROTEIN COMPOSITION
EP2351920A4 (en) TURBOCHARGER
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
EP2261482A4 (en) TURBOCHARGER
DK2373293T3 (da) Sammensætninger med reduceret dimerdannelse
BRPI0918328A2 (pt) composição e artigo
GB0819530D0 (en) Methods and compositions
BRPI0913807A2 (pt) composição e artigo
EP2350385A4 (en) Forming section
BRPI0911625A2 (pt) Métodos
BRPI0909634A2 (pt) 2-aminoquinolinas
EP2357204A4 (en) COMPOSITION